PARIS--(BUSINESS WIRE)--First paragraph, last sentence should read: The successful first case was performed by Mark Archie, MD, principal investigator for the PROMISE II trial at Harbor-UCLA Medical Center, and Nina Bowens, MD, sub-investigator for the PROMISE II trial at Harbor-UCLA Medical Center. (instead of: The successful first case was performed by Mark Archie, MD, principal investigator for the PROMISE II trial at Harbor-UCLA Medical Center.)
The corrected release reads:
FIRST PATIENT ENROLLED IN PROMISE II U.S. PIVOTAL STUDY OF LIMFLOW SYSTEM TO TREAT CHRONIC LIMB-THREATENING ISCHEMIA
Clinical Study to Evaluate Device’s Ability to Prevent Amputation and Promote Wound Healing in Patients with No Other Options
LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), announced today that the first patient has been treated in its PROMISE II U.S. pivotal trial of the LimFlow Percutaneous Deep Vein Arterialization (pDVA) System. The successful first case was performed by Mark Archie, MD, principal investigator for the PROMISE II trial at Harbor-UCLA Medical Center, and Nina Bowens, MD, sub-investigator for the PROMISE II trial at Harbor-UCLA Medical Center.
“We are pleased to be the first center in the country to treat a patient in this important trial,” said Dr. Archie. “The LimFlow System offers a promising new therapy with the potential to restore blood flow to the ischemic foot, heal wounds, and prevent major amputations in a patient population that today is unable to be treated with any current technology,”
PROMISE II is a multi-center, prospective, single-arm study being conducted in the U.S. and Japan. Using an adaptive statistical design, the study plans to enroll 60 to 120 “no option” CLTI patients. Endpoints include amputation-free survival at six months, limb salvage and wound healing, and subjects will be followed out to three years. The “no option” patients who are candidates for the PROMISE II study are no longer eligible for conventional endovascular or surgical therapy for CLTI, as determined by an independent physician committee.
When all other therapeutic options have been exhausted and a CLTI patient is facing major amputation, the minimally-invasive LimFlow system is designed to bypass blocked arteries in the leg and deliver oxygenated blood back into the foot via the veins. For many patients, restoring perfusion in the lower limbs resolves chronic pain, improves quality of life, enables wound healing and prevents major amputation.
“Treating the first patient soon after FDA approval of the trial demonstrates the enthusiasm vascular specialists have for a therapy designed to help patients keep their limbs that would otherwise face amputation,” said LimFlow CEO Dan Rose. “With the increasing prevalence of diabetes, obesity and cardiovascular disease, CLTI has become a public health crisis, recognized by the FDA in designating the LimFlow system as a Breakthrough Device. We look forward to undertaking a rigorous study of our technology to offer new hope to patients who have no other options today.”
CLTI is the most severe form of PAD and often occurs in patients suffering from such conditions as coronary artery disease, diabetes, obesity, high cholesterol and high blood pressure. Patients with CLTI often experience profound, chronic pain and develop festering wounds or infections that lead to major limb amputation, an event closely associated with increased mortality and reduced quality of life. To relieve the symptoms of CLTI, patients today are treated primarily with angioplasty or open bypass surgery. In many late-stage patients, however, neither option is feasible due to extensive disease in the target arteries or other anatomical constraints.
Click here to view a video of how the LimFlow Percutaneous Deep Vein Arterialization (pDVA) System works.
About LimFlow SA
LimFlow is a private, venture-backed medical device company transforming the treatment of chronic limb-threatening ischemia, a growing clinical need in the face of the prevalence of diabetes, heart disease, kidney disease and an aging population. For more information, visit www.limflow.com
CAUTION: The LimFlow technology is approved for investigational use only in the United States. The LimFlow System received the CE Mark in October 2016 and is currently available commercially in Europe. The LimFlow System has not been approved for sale in the USA, Canada, or Japan.